Clinical Trial

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2025-08-05; most recent amendment 2026-07-03.
Status change: Not Yet Recruiting → Recruiting 2025-10-13
Trial Details
NCT Number NCT07106762
Lead Sponsor Bristol-Myers Squibb
Conditions Urothelial Cancer
Enrollment 470 participants
Start Date 2025-09-30
Primary Completion 2029-01-26 (estimated)
Study Completion 2033-11-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-29